By Marie Rosenthal
The recent retraction of two papers that used the Surgical Outcomes Collaborative registry, developed and maintained by Surgisphere Corp., to evaluate the impact of drugs in COVID-19 patients is a cautionary tale, according to C. Michael White, PharmD, FCP, FCCP, who was not involved in both studies but was asked his thoughts about them.
The authors of the two papers, which appeared in The New England Journal of Medicine and the Lancet, retracted the papers after concerns were